【摘要】 目的探讨胸水表皮生长因子受体(EGFR)基因检测对晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗的预测价值。方法纳入62例NSCLC患者,胸水取样通过ARMS检测EGFR基因突变,随访其口服吉非替尼的有效率、疾病控制率及无进展生存期。结果 EGFR突变患者的EGFRTKI治疗的有效率及疾病控制率均优于野生型患者(P<0.05),EGFR突变患者的无进展生存期优于野生型患者,但是两者之间的差异不显著(P>0.05)。结论胸水的EGFR基因检测对于NSCLC患者的EGFR-TKI治疗具有一定的预测价值。更多还原

【Abstract】 Objective This study investigated the role of EGFR mutation detection in pleural effusion for predicting response to EGFR-TKI therapy in patients with advanced non-small cell lung cancer( NSCLC). Methods 62 patients with advanced NSCLC who were treated with Gefitinib were included in this study. Pleural effusion from these patients were collected,and EGFR mutation was examined by ARMS. Subsequently,effective rate,disease control rate and progressionfree survival were evaluated. Results The effective rate and disease control rate of EGFR-TKI treatment in patients with EGFR mutation were significantly higher than those in EGFR wild type patients( P < 0. 05). The progression-free survival of EGFR mutation patients was longer than that of EGFR wild type patients,but there was no statistically significant difference between them( P > 0. 05). Conclusion The detection of EGFR mutation in pleural effusion has certain predictive value for EGFR-TKI therapy in NSCLC patients.更多还原